Bayer

#AI #Bayer #Cradle #Drug discovery

Bayer partners with Cradle to advance AI-led drug discovery 

Pharma giant Bayer has signed a three-year strategic collaboration with biotech company Cradle to advance AI-enabled antibody discovery and optimisation.  Bayer aims to implement Cradle’s AI software platform, used for protein engineering, to scale its drug discovery and development efforts. The company intends to integrate Cradle’s platform… Read More

#Business & Investment #News

Woman suffering from hot flushes
#Bayer #FDA #Menopause #Women's health

Bayer’s new approach to hot flashes receives FDA approval

The US Food and Drug Administration (FDA) has approved Lynkuet (elinzanetant) 60mg capsules, the first and only dual neurokinin (NK) targeted therapy,1 neurokinin 1 (NK1) and neurokinin 3 (NK3) receptor antagonist, for the treatment of moderate to severe hot flashes due to menopause.  Inhibition of Substance P… Read More

#News #Regulatory

Doctor showing a model of the prostate
#Bayer #Health Canada #Oncology #Prostate cancer

Health Canada extends approval of Bayer’s darolutamide

Health Canada has granted marketing authorisation for Bayer’s oral androgen receptor inhibitor (ARi) Nubeqa (darolutamide) for the treatment of patients with metastatic castration-sensitive prostate cancer (mCSPC).   This authorisation is based on results from the Phase III ARANOTE trial, which showed that darolutamide plus ADT reduced the risk… Read More

#News #Regulatory

Test for KRAS mutation
#Bayer #KRAS #Kumquat Biosciences #Oncology #Precision medicine

Bayer and Kumquat collaborate on precision oncology

Bayer and Kumquat Biosciences have entered into an exclusive global license and collaboration agreement to develop and commercialise Kumquat’s KRAS G12D inhibitor.   Under the agreement, Kumquat is responsible for the initiation and completion of the Phase Ia study, while Bayer will complete development and commercial activities. … Read More

#Business & Investment #Cancer Research #News

Human heart
#Bayer #Cardiovascular disease #Heart failure #MHRA

UK authorises Bayer’s acoramidis for transthyretin amyloidosis

The UK Medicines and Healthcare products Regulatory Agency (MHRA) has authorised the use of Beyonttra (acoramidis) in the UK for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).  ATTR-CM is a progressive, fatal disease that presents as an infiltrative, restrictive cardiomyopathy… Read More

#News #Regulatory

Gene therapy
#Asklepios BioPharmaceutical #Bayer #Belief BioMed #Collaboration #Gene therapy

AskBio and Belief BioMed explore potential new gene therapies

Bayer AG and Asklepios BioPharmaceutical (AskBio) have announced a new strategic collaboration with Belief BioMed (BBM) to explore the potential for new gene therapies. Under the terms of the contract, the companies will combine efforts and experience in gene therapy technology to explore potential therapies in… Read More

#Business & Investment #News

Neuroscience Parkinson's disease
#Bayer #Biogen #BlueRock Therapeutics #Cell therapy #Ionis Pharmaceuticals #Mission Therapeutics #Neuroscience #Parkinson's #Small molecul #Stem cells #Vaxxinity #Vesper Bio

Exploring new frontiers in Parkinson’s Disease   

With debilitating symptoms including tremor, slow movement, rigidness and pain, Parkinson’s disease remains one of the most feared neurodegenerative conditions. DDW’s Megan Thomas reports on the latest clinical progress as pharma and biotech search for new therapies for this currently incurable condition.  Parkinson’s is the most common movement disorder, affecting… Read More

#Exclusive Content #Trends & Analysis

Degeneration of dopaminergic neuron in Parkinson's disease
#Bayer #BlueRock Therapeutics #Neurodegenerative disorders #Neuroscience #Parkinson's #Stem cells

Stem cell derived Parkinson’s therapy shows promise

A stem cell derived investigational therapy for treating Parkinson’s disease has shown promise in early clinical trials. BlueRock Therapeutics, a subsidiary of Bayer, has announced details of the positive data from a Phase I clinical trial for bemdaneprocel (BRT-DA01). The data were presented at… Read More

#News #Trending News

Treg cells
#Bayer #bit bio #BlueRock Therapeutics #Collaboration #iPSC #T cell activation

BlueRock and bit.bio sign Treg therapies discovery deal

Bayer subsidiary BlueRock Therapeutics, and bit.bio have announced a collaboration to discover and manufacture regulatory T cell (Treg) based therapies. Under the terms of the agreement, bit.bio will use its machine learning discovery platform to identify transcription factor (TF) combinations for reprogramming iPSCs into Tregs. Read More

#News

Monoclonal antibody
#Bayer #Evotec #Kidney disease #Monoclonal antibodies #Phase I trial

First patient dosed in trial of antibody for kidney disease

The first patient has been dosed in the clinical Phase I evaluation of the Sema3A monoclonal antibody, part of the Evotec-Bayer multi-target research collaboration in kidney diseases. The drug candidate, a monoclonal antibody (mAb) targeting the protein Semaphorin-3A (Sema3A), is being developed as a potential first-to-market… Read More

#News

Peptide
#Bayer #Bicycle Therapeutics #Collaboration #Oncology #Partnership #Peptides #Radiochemistry

Bayer and Bicycle collaborate on bicyclic peptides

Bayer and Bicycle Therapeutics have entered into a strategic collaboration agreement to discover, develop, manufacture, and commercialise Bicycle radioconjugates for multiple oncology targets. Bicyclic peptides are peptides consisting of 9-20 amino acids that can be synthetically manufactured and bind to targets with high affinity and selectivity,… Read More

#Cancer Research #News